Two-thirds of patients with a complete response at three months avoided cystectomy at 60 months. Among cystectomy patients, only six progressed to muscle-invasive bladder cancer, indicating low ...

Belzutifan, a HIF-2α inhibitor, is approved for von Hippel-Lindau disease and advanced renal cell carcinoma, with a focus on its safety profile. The study found 28% of patients experienced grade 3 ...

The NanoKnife System received FDA 510(k) clearance for prostate tissue ablation, utilizing irreversible electroporation technology to target tumors while preserving critical functions. The PRESERVE ...

Delayed diagnosis or treatment was the primary cause of malpractice lawsuits in testicular cancer cases, accounting for 87.5% of claims. No malpractice claims were associated with surveillance ...

Nadofaragene firadenovec offers a 66% probability of cystectomy-free survival at 60 months for BCG-unresponsive NMIBC with CIS ± Ta/T1 disease. The phase 3 study enrolled 107 patients, with 103 ...